Our data suggest that monitoring the pattern and levels of PrPC in combination with measurements of 14-3-3 level in CSF of CJD patients may be used as a predictive biomarker for CJD diagnosis and progression. The gene discussed is PRNP; the disease is Creutzfeldt Jacob disease.